Booster effect of interleukin-2 on natural killer 1.1+ cells stimulated by administration of macrophage colony-stimulating factor in mice

Journal of Immunotherapy

Volumn 26, Issue 1, 2003, Pages 21-30

  Misawa, Eriko ^a   Sakurai, Takuma ^a   Yamada, Muneo ^a   Hayasawa, Hirotoshi ^a   Motoyoshi, Kazuo ^b  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

B16 melanoma; Interleukin 2; Macrophage colony stimulating factor; Natural killer 1.1 cells

Indexed keywords

COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; MALE; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIGENS; ANTIGENS, SURFACE; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROTEINS; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY;

EID: 85026148406     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200301000-00003     Document Type: Article

References (42)

1. Stanley ER, Heard PM. Factors regulating macrophage production and growth. J Biol Chem 1977;252:4305-12.
2. Wong GG, Temple PA, Leary AC, et al. Human CSF-1: molecular cloning and expression of 4-kb cDNA encording the human urinary protein. Science 1987;235:1504-8.
3. Becker S, Warren MK, Haskill S. Colony-stimulating factor induced monocyte survival and differentiation into macrophage in serum-free cultures. J Immunol 1987;139:3703-9.
4. Motoyoshi K, Yoshida K, Hatake K, et al. Recombinant and native human urinary colony-stimulating factor directly augments granulocytic and granulocyte-macrophage colony-stimulating factor production of human peripheral blood monocytes. Exp Hematol 1989;17:68-71.
5. Warren MK, Ralph P. Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor and colony stimulating activity. J Immunol 1986;137:2281-5.
6. Hashimoto S, Yoda M, Yamada M, et al. Macrophage colony-stimulating factor induces interleukin-8 production in human monocytes. Exp Hematol 1991;24:123-8.
7. Wang JM, Griffin JD, Rambaldi A, et al. Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol 1988;141:575-87.
8. Kuhara T, Uchida K, Yamaguchi H. Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic candidia albicans infection, Antimicrob Agents Chemother 2000;44: 19-23.
9. Suzu S, Motoyoshi K. Enhancing effect of human monocyte colony-stimulating factor on monocyte tumoricidal activity. Cancer Res 1989;49:5913-7.
10. Mufson RA, Aghajaninan J, Wong G, et al. Macrophage colony-stimulating factor(M-CSF) enhances monocyte and macrophages antibody-dependent cell mediated cytotoxity. Cell Immunol 1989; 119:182-92.
11. Motoyoshi K, Takaku F, Maekawa T, et al. Protective effect of partially purified human urinary colony-stimulating factor on granulocytepenia after antitumor chemotherapy. Exp Hematol 1986;14:1069-75.
12. Masaoka T, Shibata H, Ohno R, et al. Double-blind test of human urinary colony-stimulating factor for allogenic and syngenetic bone marrow transplantation: Effectiveness of treatment and 2-year follow-up for relapse of leukemia. Br J Haematol 1990;76: 501-5.
13. Ohno R. Granulocyte colony-stimulating factor, granulocyte- macrophage colony-stimulating factor and macrophage colony- stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Leuk Res 1998;22:1143-54.
14. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993;82:1422-7.
15. Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of cloned cDNA for human interleukin-2. Nature 1983;302:305-10.
16. Ehrhardt RO, Ludviksson BR, Gray B, et al. Induction and prevention of clonic inflammation in IL-2-deficient mice. J Immunol 1997;158:566-73.
17. Henney CS, Kuribayashi K, Kern DE, et al. Interleukin-2 augments natural killer cell-activity. Nature 1981;291:335-6.
18. Grimm EA, Robb RJ, Roth JA, et al. Lymphokune-activated killer cell phenomenon III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 1983;158:1356-61.
19. Kabelits D, Pfeffer K, Steldern DV, et al. In vitro maturation of B cells in chronic lymphocytic leukemia. J Immunol 1985;135: 2876-81.
20. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
21. Pavone L, Andrulli S, Santi R, et al. Long-term treatment with low doses of interleukin-2 and interferon-a: immunologic effects in advanced renal cell cancer. Cancer Immunol Immunother 2001;50: 82-6.
22. de Jong JLO, Farmer NL, Javorsky BR, et al. Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy. Clinic Can Res 1998;5:1287-96.
23. Armstrong WS, Kazanjian P. Use of cytokines in human immunodeficiency virus-infected patient: colony-stimulating factors, erythropoetin, and interleukin-2. Clin Infect Dis 2001;32:766-73.
24. Burns LJ, Weisdorf DJ, DeFor TE, et al. Enhancement of the anti-tumor activity of a peripheral blood progenitor cells graft by mobilization with interleukin-2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp Hematol 2000;28:96-103.
25. Schmidinger M, Steger G, Wenzel C, et al. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial. J Immunother 2001;24:257-62.
26. Takahashi K, Saito S, Kamamura Y, et al. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocyte via macrophages in lung cancer patients. Cancer Immunol Immunother 2000;49:537-43.
27. Westermann J, Reich G, Kopp J, et al. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2001;49:613-20.
28. Vallera DA, Taylor PA, Aukerman SL, et al. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Cancer Res 1991;53: 4273-80.
29. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-375.
30. Herberman RB, Reynolds CW, Ortaldo JR. Mechanism of cytotoxicity by natural killer (NK) cells. Ann Rev Immunol 1986;4: 651-80.
31. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer. Blood 1990;76:2421-38.
32. Brittenden J, Heys SD, Ross J, et al. Natural killer cells and cancer. Cancer 1996;77:1226-43.
33. + cell activity in vivo. Int J Immunophamacol 1998;20:401-13.
34. Hatake K, Motoyoshi k, Ishizuka Y, et al. Purification of human urinary colony-stimulating factor by high performance liquid chromatography. J Chromatogr 1985;334:339-44.
35. Riccardi C, Puccetti P, Herbermann RB. Rapid in vivo assay of mouse natural killer cell activity. J Natl Cancer Inst 1979;63:1041-5.
36. Sakurai T, Yamada M, Shimamura S, et al. Antimetastatic effect of recombinant human macrophage colony-stimulating factor against lung and liver metastatic B16 melanoma. Cancer Immunol Immunother 1997;44:48-54.
37. Hanna N, Fidler IJ. Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst 1979;65:801-9.
38. Takeda k, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100.
39. Bock SN, Cameron RB, Kragel P, et al. Biological and antitumor effect of recombinant human macrophage colony-stimulating factor in mice. Cancer Res 1991;51:2649-54.
40. Bungard S, Flieger D, Schweitzer S, et al. The combination of interleukin-2 and interferon a effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29. Cancer Immunol Immunother 1998;46:213-20.
41. Cooley S, Burns LJ, Repka T, et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999;27:1533-41.
42. Munn DH, Cheung NK. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 1989;170:511-26.